Moneycontrol
HomeNewsBusinessStocksGlaxoSmithKline Pharma an outperformer: Karvy Stock Broking
Trending Topics
Tata Capital IPO
LG Electronics IPO GMP
Platinum Price
Glottis Share Price
Canara HSBC Life IPO

GlaxoSmithKline Pharma an outperformer: Karvy Stock Broking

Karvy Stock Broking has maintained an outperformer rating on GlaxoSmithKline Pharmaceuticals with a target of Rs 2550 in its February 15, 2011 research report.

February 19, 2011 / 15:12 IST
Story continues below Advertisement
Remove Ad

Karvy Stock Broking has maintained an outperformer rating on GlaxoSmithKline Pharmaceuticals with a target of Rs 2550 in its February 15, 2011 research report.

Read More

first published: Feb 19, 2011 02:19 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On: Facebook twitter instagram linkedin telegram youtube
Trending Topics
Sensex Today Tata Trusts LG Electronics IPO GMP Gold Price Platinum Price India at UN US Visa Canara HSBC Life IPO Arvind Kejriwal Delhi Weather
News
Business Markets Stocks India News City News Economy Mutual Funds Personal Finance IPO News Startups
Markets
Home Currencies Commodities Pre-Market IPO Global Market Bonds
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker New Fixed Deposits Fixed Deposit Comparison Fixed Income
Mutual Funds
Home MC 30 Top Ranked Funds ETFs Mutual Fund Screener
Tools
Income Tax Calculator EMI Calculator Retirement Planning Gratuity Calculator Petrol Price in India Diesel Price in India IFSC Code
Community
Stock Markets
Network 18 Sites
News18 Firstpost CNBC TV18 News18 Hindi Cricketnext Overdrive
Quick Links
About Us Contact Us Advisory Alert Advertise with Us Disclaimer Privacy Policy Cookie Policy Terms & Conditions Financial Terms (Glossary) Sitemap Investors
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.